Top Challenges That Impacted the Evolving Healthcare Landscape in 2023
Marc Samuels, JD, MPH
December 5, 2023
2023 brought significant changes to the healthcare landscape, encompassing the Inflation Reduction Act (IRA), navigating an unprecedented array of diagnostic policies and regulations, and managing the evolving financial environment. As a look back, we asked the ADVI team, “What was the biggest challenge or opportunity in the 2023 evolving healthcare landscape from your area of expertise?” Here’s what they shared.
Lindsay Bealor Greenleaf, federal and state policy solution leader at ADVI, shares that the IRA and government price controls at the federal and state levels were top focus areas this year.
Marc Samuels, ADVI CEO and president, discusses some of the biggest challenges from 2023 including the IRA and its impact on oncology.
Learn More
Stay ahead of the curve as you look toward 2024. Get in touch today to gain expert insights and strategic counsel on the evolving healthcare landscape.
Marc Samuels, JD, MPH
Chief Executive Officer
Lindsay Bealor Greenleaf, JD, MBA
Senior Vice President, Market Access and Policy Strategy
CEO insights
Related articles
Real analysis from people who’ve been there
ADVI Health Accelerates Insights with Monthly Medicare Data
ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – …
Why Clinical Laboratories Should Consider Weighing In on CMS and CDC’s New CLIA Request for Information
An opportunity for laboratories to help shape the future of CLIA regulation On July 16, 2026, the Centers for Medicare …
RAND/UCLA Modified Delphi Panels
ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …
Caitlin Sheetz, MPH
June 23, 2026
The MolDX Technical Assessment: How to Move Your Test from “Not Successful” to Medicare Coverage Success
In the laboratory space, the MolDX Technical Assessment (TA) is often the moment where the gap between “a great test” …
CRUSH and Genetic and Molecular Laboratories: A Potential Shift in Medicare Oversight
Genetic, molecular, and reference laboratories are closely watching a new Medicare concept known as CRUSH- short for Comprehensive Regulations to …
March Is Colorectal Cancer Awareness Month: Why CMS’s Proposed NCD 210.3 Update Could Accelerate Patient‑Centered Screening Access
Colorectal cancer (CRC) screening saves lives, but only when patients are able to access care in a way that meets …
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
A New Era for Cancer Detection Begins with the Sewell MCED Law
We are seeing a long‑anticipated and important policy inflection point. By now you might have heard that Congress passed the …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.